Internal Medicine, Hematology & Oncology · New York, NY
NPI
1538193446
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
1275 York Ave
New York, NY, 10065
Phone (212) 639-5720
Groups this clinician bills Medicare through
Medicare paid, 2024
$33K
312 services
Medicare patients, 2024
108
Average age 73
Drug cost, 2024
$1.3M
252 prescriptions
Company payments, 2025
$38K
From 9 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by William D Tap was code 99214 (office e&m - established), 142 times for 67 patients. In total William D Tap billed 312 services in 12 codes, and Medicare paid $33K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2011-05-25.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 142 | 67 | $87.74 | $12K |
| 99215 Office E&M - Established | Office | 113 | 44 | $134.79 | $15K |
By year: 2022 $36K for 323 services; 2023 $37K for 358 services; 2024 $33K for 312 services.
Medicare prescription drug claims, 2024
In 2024, the drug William D Tap prescribed most often to Medicare patients was Imatinib Mesylate, with 73 prescriptions and refills. In total William D Tap wrote 252 Medicare prescriptions that cost $1.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Imatinib Mesylate Generic | 73 | 81 | 12 | $165K |
| Gleevec Imatinib Mesylate | 20 | 26 | Under 11 | $214K |
| Verzenio Abemaciclib | 14 | 14 | Under 11 | $218K |
| Dexamethasone Generic | 14 | 14 | Under 11 | $240 |
| Amlodipine Besylate Generic | 13 | 13 | Under 11 | $190 |
| Cabometyx Cabozantinib S-Malate | 13 | 13 | Under 11 | $310K |
| Votrient Pazopanib Hcl | 11 | 11 | Under 11 | $85K |
Brand drugs: 71 claims; generic drugs: 181 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid William D Tap $38K ($38K in general payments such as food, travel and fees) from 9 companies. The largest payer was Daiichi Sankyo Inc. with $11K.
| Company | Payments | Amount |
|---|---|---|
| Daiichi Sankyo Inc. 4568.T | 9 | $11K |
| EMD Serono Research & Development Institute, Inc. MRK.DE | 2 | $6,373 |
| Recordati_rare_diseases_inc. | 6 | $6,344 |
| Ipsen Bioscience Inc. IPN.PA | 1 | $5,460 |
| EMD Serono, Inc. MRK.DE | 6 | $5,212 |
| GlaxoSmithKline, LLC. GSK | 1 | $1,900 |
| Deciphera Pharmaceuticals Inc. | 4 | $1,699 |
| Merck KGaA MRK.DE | 1 | $525 |
| Servier BioInnovation | 1 | $64.84 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.